Metformina + Sitagliptina Tolife

Metformin Hydrochloride, the active ingredient in Metformina + Sitagliptina Tolife, is a biguanide presented as a tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, often in combination with other antidiabetic agents.

GNH USA supplies Metformina + Sitagliptina Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable delivery.

Metformina + Sitagliptina Tolife combines metformin and sitagliptin to manage hyperglycemia in type 2 diabetes.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Inadequate glycemic control with metformin alone: provides additional DPP‑4 inhibition to achieve target HbA1c. - Combination therapy with insulin: reduces required insulin dose while maintaining glucose control.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycemia: especially when used with sulfonylureas or insulin. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Severe hypoglycemia: prolonged low blood glucose levels. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Allergic reactions: rash, itching, or angioedema. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: worsening kidney function, particularly in high‑risk patients.

Precautions should be observed when prescribing Metformina + Sitagliptina Tolife.

- Renal function: assess eGFR before initiating and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Lactic acidosis risk: avoid in patients with hypoxia, heart failure, or severe infection. - Pregnancy: safety not established; weigh benefits against potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Metformina + Sitagliptina Tolife may interact with several medicines.

Major Interactions (Avoid): - Severe renal impairment: contraindicated due to risk of metformin accumulation. - Iodinated contrast agents: may precipitate acute kidney injury, increasing metformin levels. - Strong CYP2C8 inhibitors: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increased risk of hypoglycemia; monitor blood glucose. - Insulin: may require dose adjustment to prevent hypoglycemia. - Diuretics: can affect renal clearance of metformin; monitor renal function.